The company has significantly improved its course of a new treatment for amyloid heart disease, leveraging Attruby. Early patient data suggests potential outcomes for individuals affected by this severe condition. The https://biotech805482.ourcodeblog.com/42534371/firm-improves-amyloidosis-treatment-through-the-drug